Allergy Therapeutics plc
Allergy Therapeutics

Allergy Therapeutics share price, news, views and interviews

Allergy Therapeutics Plc are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.

Allergy Therapeutics believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. 

What makes Allergy Therapeutics different?

Allergy Therapeutics ultra-short course treatments consist of 6 injections compared to daily tablets or an average treatment in the market of a 12-15 course of injections. Our approach offers the simplicity of fewer injections, increased tolerability and demonstrated efficacy.

The company’s adjuvant technologies improve therapies by allowing them to increase efficacy. They are further developing this concept in their specialist business, Bencard Adjuvant Systems; improving health and evaluating vaccinations for infectious diseases and cancer treatments.

Allergy Therapeutics plc

Their values have created a culture based around vision, commitment and humanity. The company take extraordinary ideas and bring them to market – enhancing treatments and transforming people’s lives.

Don't miss out --->

Receive this company's news, reports, interviews in your inbox, as we post it.

We don’t spam! Read our privacy policy for more info.

Share this page

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Allergy Therapeutics plc

Allergy Therapeutics share price

Fundamentals

Latest Allergy Therapeutics News

Interviews

Questions & Answers

Broker Notes & Comments

Allergy Therapeutics share price

Fundamentals

Share this page

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.